[开放获取]    中国皮肤结核临床诊疗专家共识（2024版）

doi:10.35541/cjd.20230354

Abstract

Abstract: 【Abstract】 Cutaneous tuberculosis is a chronic infectious skin disease caused by Mycobacterium tuberculosis complex. It has various clinical manifestations and is difficult to be accurately diagnosed. Delayed diagnosis may lead to serious damage to the skin and soft tissues. The diagnosis of cutaneous tuberculosis requires a comprehensive assessment of clinical, pathological, and laboratory findings. A long‐course combination antibiotic therapy is commonly needed for the treatment of cutaneous tuberculosis, and early standardized diagnosis and treatment are the key to ensuring a good prognosis. This expert consensus was developed based on Chinese and international literature and guidelines on cutaneous tuberculosis and tuberculosis, aiming to standardize the diagnostic procedure and improve the treatment outcomes of cutaneous tuberculosis.

Key words: Tuberculosis, Tuberculosis, cutaneous, Mycobacterium tuberculosis, Diagnosis, Therapy, Expert consensus

CLC Number:

Mycobacteriosis Research Group, China “Belt and Road” Dermatology Alliance, Division of Dermatology and STI Diagnosis, Chinese Association on Leprosy. Expert consensus on the clinical diagnosis and treatment of cutaneous tuberculosis in China （2024）[J]. Chinese Journal of Dermatology, 2024, 57(5): 426-434.doi:10.35541/cjd.20230354

References ［77］

［1］	BayBay H, Senhaji I, Zinoun S, et al. Cutaneous tuberculosis in children from the northeastern region of Morocco［J］. Arch Pediatr, 2021,28（6）:491⁃495. doi: 10.1016/j.arcped.2021.04. 011.
［2］	Sethuraman G, Ramesh V. Cutaneous tuberculosis in children［J］. Pediatr Dermatol, 2013,30（1）:7⁃16. doi: 10.1111/j.1525⁃1470.2012.01794.x.
［3］	Zawirska A, Adamski Z, Stawicka E, et al. Cutaneous squamous cell carcinoma developing in lupus vulgaris exfoliativus persistent for 40 years［J］. Int J Dermatol, 2009,48（2）:125⁃127. doi: 10.1111/j.1365⁃4632.2009.03850.x.
［4］	World Health Organization. Global tuberculosis report 2022［R/OL］. Geneva: World Health Organization, 2022［2023⁃06⁃18］. https://iris.who.int/bitstream/handle/10665/363752/9789240061729⁃eng.pdf?sequence=1.
［5］	Kozińska M, Augustynowicz⁃Kopeć E, Gamian A, et al. Cutaneous and pulmonary tuberculosis⁃diagnostic and therapeutic difficulties in a patient with autoimmunity［J］. Pathogens, 2023,12（2）:331. doi: 10.3390/pathogens12020331.
［6］	Kivanç⁃Altunay I, Baysal Z, Ekmekçi TR, et al. Incidence of cutaneous tuberculosis in patients with organ tuberculosis［J］. Int J Dermatol, 2003,42（3）:197⁃200. doi: 10.1046/j.1365⁃4362.2003.01762.x.
［7］	Santos JB, Figueiredo AR, Ferraz CE, et al. Cutaneous tuberculosis: epidemiologic, etiopathogenic and clinical aspects ⁃ part I［J］. An Bras Dermatol, 2014,89（2）:219⁃228. doi: 10.1590/abd1806⁃4841.20142334.
［8］	Jiang H, Jin Y, Vissa V, et al. Molecular characteristics of Mycobacterium tuberculosis strains isolated from cutaneous tuberculosis patients in China［J］. Acta Derm Venereol, 2017,97（4）:472⁃477. doi: 10.2340/00015555⁃2577.
［9］	Mei YM, Zhang WY, Sun JY, et al. Genomic characteristics of Mycobacterium tuberculosis isolates of cutaneous tuberculosis［J］. Front Microbiol, 2023,14:1165916. doi: 10.3389/fmicb.2023. 1165916.
［10］	Rahlwes KC, Dias B, Campos PC, et al. Pathogenicity and virulence of Mycobacterium tuberculosis［J］. Virulence, 2023,14（1）:2150449. doi: 10.1080/21505594.2022.2150449.
［11］	Sia JK, Rengarajan J. Immunology of Mycobacterium tuberculosis infections［J］. Microbiol Spectr, 2019,7（4）:10.1128/microbiolspec. GPP3⁃0022⁃2018. doi: 10.1128/microbiolspec.GPP3⁃0022⁃2018.
［12］	Chandra P, Grigsby SJ, Philips JA. Immune evasion and provocation by Mycobacterium tuberculosis［J］. Nat Rev Microbiol, 2022,20（12）:750⁃766. doi: 10.1038/s41579⁃022⁃00763⁃4.
［13］	Flynn JL, Chan J. Immune cell interactions in tuberculosis［J］. Cell, 2022,185（25）:4682⁃4702. doi: 10.1016/j.cell.2022.10.025.
［14］	Griffiths CEM, Barker J, Bleiker TO, et al. Rook′s textbook of dermatology［M］. New Jersey: Wiley⁃Blackwell, 2016.
［15］	Hill MK, Sanders CV. Cutaneous tuberculosis［J］. Microbiol Spectr, 2017,5（1）:10.1128/microbiolspec.TNMI7⁃0010⁃2016. doi: 10.1128/microbiolspec.TNMI7⁃0010⁃2016.
［16］	Beyt BE Jr, Ortbals DW, Santa Cruz DJ, et al. Cutaneous mycobacteriosis: analysis of 34 cases with a new classification of the disease［J］. Medicine （Baltimore）, 1981,60（2）:95⁃109.
［17］	Bravo FG, Gotuzzo E. Cutaneous tuberculosis［J］. Clin Dermatol, 2007,25（2）:173⁃180. doi: 10.1016/j.clindermatol.2006.05.005.
［18］	Santos JB, Figueiredo AR, Ferraz CE, et al. Cutaneous tuberculosis: diagnosis, histopathology and treatment ⁃ partⅡ［J］. An Bras Dermatol, 2014,89（4）:545⁃555. doi: 10.1590/abd1806⁃4841.20142747.
［19］	Zhang J, Fan YK, Wang P, et al. Cutaneous tuberculosis in China ⁃ a multicentre retrospective study of cases diagnosed between 1957 and 2013［J］. J Eur Acad Dermatol Venereol, 2018,32（4）:632⁃638. doi: 10.1111/jdv.14851.
［20］	Pandhi D, Reddy BS, Chowdhary S, et al. Cutaneous tuberculosis in Indian children: the importance of screening for involvement of internal organs［J］. J Eur Acad Dermatol Venereol, 2004,18（5）:546⁃551. doi: 10.1111/j.1468⁃3083.2004.00970.x.
［21］	Kumar B, Rai R, Kaur I, et al. Childhood cutaneous tuberculosis: a study over 25 years from northern India［J］. Int J Dermatol, 2001,40（1）:26⁃32. doi: 10.1046/j.1365⁃4362.2001. 01165.x.
［22］	Mann D, Sant′Anna FM, Schmaltz C, et al. Cutaneous tuberculosis and HIV infection at a referral centre in Rio de Janeiro, Brazil［J］. Mem Inst Oswaldo Cruz, 2018,113（9）:e180184. doi: 10.1590/0074⁃02760180184.
［23］	Ben Jazia E, Hachfi W, Trimech M, et al. Detection of mycobacterial tuberculosis DNA in lichen scrofulosorum［J］. J Am Acad Dermatol, 2006,55（2 Suppl）:S54⁃55. doi: 10.1016/j.jaad.2005.08.048.
［24］	Chuang YH, Kuo TT, Wang CM, et al. Simultaneous occurrence of papulonecrotic tuberculide and erythema induratum and the identification of Mycobacterium tuberculosis DNA by polymerase chain reaction［J］. Br J Dermatol, 1997,137（2）:276⁃281. doi: 10.1046/j.1365⁃2133.1997.18201916.x.
［25］	Vieites B, Suárez⁃Peñaranda JM, Pérez Del Molino ML, et al. Recovery of Mycobacterium tuberculosis DNA in biopsies of erythema induratum⁃⁃results in a series of patients using an improved polymerase chain reaction technique［J］. Br J Dermatol, 2005,152（6）:1394⁃1396. doi: 10.1111/j.1365⁃2133. 2005.06650.x.
［26］	Kaul S, Jakhar D, Mehta S, et al. Cutaneous tuberculosis. PartⅡ: complications, diagnostic workup, histopathologic features, and treatment［J］. J Am Acad Dermatol, 2023,89（6）:1107⁃1119. doi: 10.1016/j.jaad.2021.12.064.
［27］	Barbagallo J, Tager P, Ingleton R, et al. Cutaneous tuberculosis: diagnosis and treatment［J］. Am J Clin Dermatol, 2002,3（5）:319⁃328. doi: 10.2165/00128071⁃200203050⁃00004.
［28］	Sharma S, Sehgal VN, Bhattacharya SN, et al. Clinicopathologic spectrum of cutaneous tuberculosis: a retrospective analysis of 165 Indians［J］. Am J Dermatopathol, 2015,37（6）:444⁃450. doi: 10.1097/DAD.0000000000000297.
［29］	Brito AC, Oliveira C, Unger DA, et al. Cutaneous tuberculosis: epidemiological, clinical, diagnostic and therapeutic update［J］. An Bras Dermatol, 2022,97（2）:129⁃144. doi: 10.1016/j.abd.2021. 07.004.
［30］	Kathuria P, Agarwal K, Koranne RV. The role of fine⁃needle aspiration cytology and Ziehl Neelsen staining in the diagnosis of cutaneous tuberculosis［J］. Diagn Cytopathol, 2006,34（12）:826⁃9. doi: 10.1002/dc.20534.
［31］	Rademaker M, Lowe DG, Munro DD. Erythema induratum （Bazin's disease）［J］. J Am Acad Dermatol, 1989,21（4 Pt 1）:740⁃5. doi: 10.1016/s0190⁃9622（89）70248⁃6.
［32］	Tirumalae R, Yeliur IK, Antony M, et al. Papulonecrotic tuberculid⁃clinicopathologic and molecular features of 12 Indian patients［J］. Dermatol Pract Concept, 2014,4（2）:17⁃22. doi: 10. 5826/dpc.0402a03.
［33］	何翼君, 张浩然, 辛赫男, 等. 结核菌素皮肤试验的应用及其优化［J］. 中国防痨杂志, 2021,43（3）:204⁃210. doi: 10.3969/j.issn.1000⁃6621.2021.03.003.
［34］	都伟欣, 赵爱华, 王国治, 等. 结核菌素类产品的发展历程概述［J］. 中国防痨杂志, 2019,41（10）:1080⁃1083. doi: 10.3969/j.issn.1000⁃6621.2019.10.003.
［35］	Ramam M, Malhotra A, Tejasvi T, et al. How useful is the Mantoux test in the diagnosis of doubtful cases of cutaneous tuberculosis?［J］. Int J Dermatol, 2011,50（11）:1379⁃1382. doi: 10.1111/j.1365⁃4632.2011.04971.x.
［36］	Ramesh V, Gupta J. Cutaneous tuberculosis of the pinna［J］. Int J Dermatol, 2021,60（3）:363⁃367. doi: 10.1111/ijd.15249.
［37］	Nayak S, Acharjya B. Mantoux test and its interpretation［J］. Indian Dermatol Online J, 2012,3（1）:2⁃6. doi: 10.4103/2229⁃5178.93479.
［38］	Zhou G, Luo Q, Luo S, et al.Interferon⁃γ release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta⁃analysis ［J］. Lancet Infect Dis, 2020,20（12）:1457⁃1469. doi: 10.1016/S1473⁃3099（20）30276⁃0.
［39］	Santin M, García⁃García JM, Domínguez J, et al. Guidelines for the use of interferon⁃γ release assays in the diagnosis of tuberculosis infection［J］. Enferm Infecc Microbiol Clin, 2016,34（5）:303.e1⁃13. doi: 10.1016/j.eimc.2015.11.022.
［40］	Chen Y, Jiang H, Zhang W, et al. Diagnostic value of T⁃SPOT.TB test in cutaneous mycobacterial infections［J］. Acta Derm Venereol, 2018,98（10）:989⁃990. doi: 10.2340/00015555⁃3011.
［41］	Tebruegge M, Connell T, Ritz N, et al. Discordance between TSTs and IFN⁃gamma release assays: the role of NTM and the relevance of mycobacterial sensitins［J］. Eur Respir J, 2010,36（1）:214⁃215; author reply 215⁃216. doi: 10.1183/09031936. 00025510.
［42］	Siegel S, Cavanaugh M, Ku JH, et al. Specificity of QuantiFERON⁃TB Plus, a new⁃generation interferon gamma release assay［J］. J Clin Microbiol, 2018,56（12）:e00629⁃18. doi: 10.1128/JCM.00629⁃18.
［43］	Pan L, Jia H, Liu F, et al. Risk factors for false⁃negative T⁃SPOT.TB assay results in patients with pulmonary and extra⁃pulmonary TB［J］. J Infect, 2015,70（4）:367⁃380. doi: 10.1016/j.jinf.2014.12.018.
［44］	中华人民共和国国家卫生和计划生育委员会. 肺结核诊断标准（WS 288⁃2017）［J］. 新发传染病电子杂志, 2018,3（1）:59⁃61. doi: 10.3877/j.issn.2096⁃2738.2018.01.017.
［45］	Almaguer⁃Chávez J, Ocampo⁃Candiani J, Rendón A. Current panorama in the diagnosis of cutaneous tuberculosis［J］. Actas Dermosifiliogr, 2009,100（7）:562⁃570.
［46］	Pfyffer GE, Wittwer F. Incubation time of mycobacterial cultures: how long is long enough to issue a final negative report to the clinician?［J］. J Clin Microbiol, 2012,50（12）:4188⁃4189. doi: 10.1128/JCM.02283⁃12.
［47］	Dong B, He Z, Li Y, et al. Improved conventional and new approaches in the diagnosis of tuberculosis［J］. Front Microbiol, 2022,13:924410. doi: 10.3389/fmicb.2022.924410.
［48］	Said HM, Kock MM, Ismail NA, et al. Comparison between the BACTEC MGIT 960 system and the agar proportion method for susceptibility testing of multidrug resistant tuberculosis strains in a high burden setting of South Africa［J］. BMC Infect Dis, 2012,12:369. doi: 10.1186/1471⁃2334⁃12⁃369.
［49］	Kassaza K, Orikiriza P, Llosa A, et al. Lowenstein⁃Jensen selective medium for reducing contamination in Mycobacterium tuberculosis culture［J］. J Clin Microbiol, 2014,52（7）:2671⁃2673. doi: 10.1128/JCM.00749⁃14.
［50］	Butler WR, Guthertz LS. Mycolic acid analysis by high⁃performance liquid chromatography for identification of Mycobacterium species［J］. Clin Microbiol Rev, 2001,14（4）:704⁃726, table of contents. doi: 10.1128/CMR.14.4.704⁃726.2001.
［51］	Wu X, Tan G, Yang J, et al. Prediction of Mycobacterium tuberculosis drug resistance by nucleotide MALDI⁃TOF⁃MS［J］. Int J Infect Dis, 2022,121:47⁃54. doi: 10.1016/j.ijid.2022.04. 061.
［52］	Robinne S, Saad J, Morsli M, et al. Rapid identification of Mycobacterium tuberculosis complex using mass spectrometry: a proof of concept［J］. Front Microbiol, 2022,13:753969. doi: 10.3389/fmicb.2022.753969.
［53］	Gholoobi A, Masoudi⁃Kazemabad A, Meshkat M, et al. Comparison of culture and PCR methods for diagnosis of Mycobacterium tuberculosis in different clinical specimens［J］. Jundishapur J Microbiol, 2014,7（2）:e8939. doi: 10.5812/jjm. 8939.
［54］	Tan SH, Tan BH, Goh CL, et al. Detection of Mycobacterium tuberculosis DNA using polymerase chain reaction in cutaneous tuberculosis and tuberculids［J］. Int J Dermatol, 1999,38（2）:122⁃127. doi: 10.1046/j.1365⁃4362.1999.00576.x.
［55］	Agarwal P, Singh EN, Agarwal US, et al. The role of DNA polymerase chain reaction, culture and histopathology in the diagnosis of cutaneous tuberculosis［J］. Int J Dermatol, 2017,56（11）:1119⁃1124. doi: 10.1111/ijd.13708.
［56］	严慧, 朱庆义. 聚合酶链反应鉴定结核分枝杆菌常用靶基因序列的研究进展［J］. 中华临床实验室管理电子杂志, 2016,4（3）:159⁃163. doi: 10.3877/cma.j.issn.2095⁃5820.2016.03.007.
［57］	Makeshkumar V, Madhavan R, Narayanan S. Polymerase chain reaction targeting insertion sequence for the diagnosis of extrapulmonary tuberculosis［J］. Indian J Med Res, 2014,139（1）:161⁃166.
［58］	Tan SH, Tan HH, Sun YJ, et al. Clinical utility of polymerase chain reaction in the detection of Mycobacterium tuberculosis in different types of cutaneous tuberculosis and tuberculids［J］. Ann Acad Med Singap, 2001,30（1）:3⁃10.
［59］	World Health Organization. Xpert MTB/RIF implementation manual: technical and operational ′how⁃to′; practical considerations［M/OL］. Geneva: World Health Organization, 2014［2023⁃06⁃18］. https://iris.who.int/bitstream/handle/10665/112469/9789241506700_eng.pdf?sequence=1.
［60］	Mekkaoui L, Hallin M, Mouchet F, et al. Performance of Xpert MTB/RIF Ultra for diagnosis of pulmonary and extra⁃pulmonary tuberculosis, one year of use in a multi⁃centric hospital laboratory in Brussels, Belgium［J/OL］. PLoS One, 2021,16（4）:e0249734. doi: 10.1371/journal.pone.0249734.
［61］	Denkinger CM, Schumacher SG, Boehme CC, et al. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta⁃analysis［J］. Eur Respir J, 2014,44（2）:435⁃446. doi:10.1183/09031936.00007814.
［62］	Lawn SD, Zumla AI. Diagnosis of extrapulmonary tuberculosis using the Xpert® MTB/RIF assay［J］. Expert Rev Anti Infect Ther, 2012,10（6）:631⁃635. doi: 10.1586/eri.12.43.
［63］	Sun W, Lu Z, Yan L. Clinical efficacy of metagenomic next⁃generation sequencing for rapid detection of Mycobacterium tuberculosis in smear⁃negative extrapulmonary specimens in a high tuberculosis burden area［J］. Int J Infect Dis, 2021,103:91⁃96. doi: 10.1016/j.ijid.2020.11.165.
［64］	Chen P, Sun W, He Y. Comparison of metagenomic next⁃generation sequencing technology, culture and GeneXpert MTB/RIF assay in the diagnosis of tuberculosis［J］. J Thorac Dis, 2020,12（8）:4014⁃4024. doi: 10.21037/jtd⁃20⁃1232.
［65］	中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 肺结核基层诊疗指南（实践版·2018）［J］. 中华全科医师杂志, 2019,18（8）:718⁃722. doi: 10.3760/cma.j.issn.1671⁃7368. 2019.08.003.
［66］	Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug⁃susceptible tuberculosis［J］. Clin Infect Dis, 2016,63（7）:e147⁃e195. doi: 10.1093/cid/ciw376.
［67］	World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment ⁃ drug⁃susceptible tuberculosis treatment［M/OL］. Geneva: World Health Organization, 2022.［2023⁃06⁃18］. https://iris.who.int/bitstream/handle/10665/353829/ 9789240048126⁃eng.pdf?sequence=1.
［68］	World Health Organization. Dose optimization of rifampicin, isoniazid, pyrazinamide and ethambutol in the treatment of drug⁃susceptible tuberculosis［EB/OL］. Geneva: World Health Organization, 2022.［2023⁃06⁃18］. https://www.who.int/docs/default⁃source/hq⁃tuberculosis/dose⁃optimization⁃concept⁃note.pdf?sfvrsn=934ab3e2_2.
［69］	中国疾病预防控制中心结核病预防控制中心. 中国结核病防治工作技术指南（2021年版）［M］. 北京: 人民卫生出版社, 2022.
［70］	Mei Y, Zhang W, Shi Y, et al. Cutaneous tuberculosis and nontuberculous mycobacterial infections at a national specialized hospital in China［J］. Acta Derm Venereol, 2019,99（11）:997⁃1003. doi: 10.2340/00015555⁃3283.
［71］	Singal A, Kaur I, Jakhar D, et al. Clinicoepidemiological characteristics of cutaneous tuberculosis in 1458 Indian patients: a retrospective analytical study from a tertiary care center［J］. Int J Dermatol, 2022,61（8）:1012⁃1022. doi: 10.1111/ijd.16267.
［72］	Ranawaka RR, Abeygunasekara PH, Perera E, et al. Clinico⁃histopathological correlation and the treatment response of 20 patients with cutaneous tuberculosis［J］. Dermatol Online J, 2010,16（8）:13.
［73］	World Health Organization. WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents［M/OL］. Geneva: World Health Organization, 2022［2023⁃06⁃18］. https://iris.who.int/bitstream/handle/10665/352522/9789240046764⁃eng.pdf?sequence=1.
［74］	中华医学会结核病学分会. 老年肺结核诊断与治疗专家共识（2023版）［J］. 中华结核和呼吸杂志, 2023,46（11）:1068⁃1084. doi: 10.3760/cma.j.cn112147⁃20230921⁃00182.
［75］	van Zyl L, du Plessis J, Viljoen J. Cutaneous tuberculosis overview and current treatment regimens［J］. Tuberculosis （Edinb）, 2015,95（6）:629⁃638. doi: 10.1016/j.tube.2014.12.006.
［76］	World Health Organization. WHO consolidated guidelines on drug⁃resistant tuberculosis treatment［M］. Geneva:World Health Organization, 2019.
［77］	中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识（2019年版）［J］. 中华结核和呼吸杂志, 2019,42（10）:733⁃749. doi: 10.3760/cma.j.issn.1001⁃0939.2019.10. 006.

[1]	Writing Committee Expert Group on “Treatment of Extramammary Paget′s Disease: a Chinese Expert Consensus Statement （）”. Treatment of extramammary Paget′s disease: a Chinese expert consensus statement （2024） [J]. Chinese Journal of Dermatology, 2024, 57(5): 400-408.
[2]	China Dermatologist Association. Guidelines for the management of chronic pruritus （2024） [J]. Chinese Journal of Dermatology, 2024, 57(5): 387-399.
[3]	China Dermatologist Association, Combination of Traditional and Western Medicine Dermatology. Diagnosis and treatment of erythrodermic psoriasis: a Chinese expert consensus statement （2024） [J]. Chinese Journal of Dermatology, 2024, 57(5): 409-417.
[4]	Mycology Group, Combination of Traditional and Western Medicine Dermatology, Chinese Antifungal-Resistant Dermatophytosis Expert Consensus Group. Expert consensus on the diagnosis, treatment, prevention and control of antifungal-resistant dermatophyte infections in China （2024） [J]. Chinese Journal of Dermatology, 2024, 57(5): 418-425.
[5]	Chinese Society of Dermatology, China Dermatologist Association, Chinese Association of Integrative Medicine Board of Dermatovenereology. Expert consensus on the clinical application of chemical peeling in China （2024 public version） [J]. Chinese Journal of Dermatology, 2024, 0(5): 20230620-e20230620.
[6]	Yue Shuzhen, Shu Ye, Luo Yangyang, Li Keyao, Zhang Yuanyuan, Tang Jianping, Wei Zhu. Efficacy and safety of omalizumab in the treatment of chronic urticaria in children: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(4): 354-358.
[7]	Ge Xinhong, Ma Yingdong, Jiao Yaning, Liu Lingling, Zhou Mei, Zi Wei, Li Bowen. Analysis of efficacy and safety of 532-nm picosecond laser in the treatment of early-stage facial seborrheic keratosis [J]. Chinese Journal of Dermatology, 2024, 57(4): 359-362.
[8]	Liu Yi, Qu Ying, Lei Wenzhi, Liu Xiaogang, Pan Weihua, Zhang Chao. Clinical efficacy of salt-packing therapy in the treatment of pyogenic granuloma [J]. Chinese Journal of Dermatology, 2024, 0(4): 20230553-e20230553.
[9]	Zhang Dimin, Cao Cheng, Zhou Miaoni, Sheng Anqi, Lin Fuquan, Xu Ai′e. Analysis of disease control rate and its influencing factors in patients with progressive non-segmental vitiligo after combined treatment with compound betamethasone injection [J]. Chinese Journal of Dermatology, 2024, 57(4): 350-354.
[10]	Wang Yimeng, Wu Wenting, Zhang Qian, Zhang Chunlei, Li Weiwei. Clinical and pathological diagnoses of 389 patients with primary solid tumors localized in the perianal and external genitalia regions [J]. Chinese Journal of Dermatology, 2024, 57(4): 316-323.
[11]	Yan Rufan, Liao Jieyue, Guo Ziyu, Yao Nan, Zhou Wenyu, Luo Shuaihantian, Zhang Guiying, Zhao Ming. Pathogenesis and targeted therapy of pemphigus [J]. Chinese Journal of Dermatology, 2024, 57(4): 374-378.
[12]	Yang Yuting, Gu Guolin, Wu Minjuan, Sheng Zhijie, Li Jin, Mo Xingfan, Wu Minzhi, Xu Ping, . Application of serum fibronectin in combination with non-treponemal antibody testing in the exclusion of asymptomatic neurosyphilis among serofast syphilis patients: a preliminary study [J]. Chinese Journal of Dermatology, 2024, 57(3): 246-249.
[13]	Hospital for Skin Diseases, Chinese Academy of Medical Sciences, National Center for STD Control, Chinese Center for Disease Control and Prevention, Venereology Group, Chinese Society of Dermatology, Chinese Association Rehabilitation of Dermatology . Chinese expert consensus on the diagnosis and treatment of Mycoplasma genitalium infection （2024） [J]. Chinese Journal of Dermatology, 2024, 57(3): 201-208.
[14]	Wang Liuyuan, Zhang Xiaohui, Luo Danyang, Ke Wujian, Xue Yaohua, Huang Jinmei, Li Changchang, Zhao Peizhen, Yang Ligang, . A survey on the current status of standardized diagnosis and treatment services for sexually transmitted diseases in medical institutions in Guangdong province [J]. Chinese Journal of Dermatology, 2024, 57(3): 218-223.
[15]	Chen Nana, Li Zheng, Zhang Jie, Li Shishen, Li Wei. Early infection status among 147 cases of latent syphilis in Nanning city: a cross-sectional survey [J]. Chinese Journal of Dermatology, 2024, 57(3): 213-217.

Expert consensus on the clinical diagnosis and treatment of cutaneous tuberculosis in China （2024）

PDF

Knowledge

Abstract

Cite this article

share this article

References ［77］

Related Articles 15

Metrics

Comments

Recommended 10